Associated Papers
Association of UGT1A9 Polymorphisms with Cardiac Injury Biomarkers and Clinical Features.
Özen M et al.
Pharmaceuticals (basel, Switzerland), 2025
Dolutegravir metabolism: impact of genetic variations on uridine diphosphate glucuronosyltransferase subfamilies.
Tagawa K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2025
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K et al.
Toxicology Mechanisms and Methods, 2023
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Naagaard MD et al.
British Journal of Clinical Pharmacology, 2022
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
Seneviratne HK et al.
Acs Pharmacology & Translational Science, 2021
The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ et al.
Acta Pharmacologica Sinica, 2017
Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity.
Yuan LM et al.
Scientific Reports, 2016
Dimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities.
Liu YQ et al.
Scientific Reports, 2016
Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H et al.
Biochemical Pharmacology, 2011
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
Ramírez J et al.
Future Oncology (london, England), 2010
Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
Johnson LA et al.
European Journal of Clinical Pharmacology, 2008
Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).
Takahashi H et al.
Basic & Clinical Pharmacology & Toxicology, 2008
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Fujita K et al.
Cancer Chemotherapy and Pharmacology, 2007
Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.
Mehlotra RK et al.
European Journal of Clinical Pharmacology, 2007
Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.
Thomas SS et al.
Human Mutation, 2006
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity.
Yamanaka H et al.
Pharmacogenetics, 2004
Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.
Ehmer U et al.
Hepatology (baltimore, Md.), 2004